RenovoRx, Inc. (RNXT) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2025, RenovoRx reported revenue of $1.1M, up 2511.6% from $43,000 the year before. Net income was -$11.2M (a -994.5% net margin), or -$0.32 per diluted share. Gross margin was 70.9% and operating margin was -1114.0%. Operating activities generated -$11.0M of cash, leaving -$11.0M of free cash flow. At fiscal year end, RenovoRx held $8.1M in total assets against $2.7M in total liabilities, including $7.0M of cash and equivalents.
Open the full interactive RenovoRx financials → Quarterly statements, key ratios, valuation history and price charts.
RenovoRx Key Stats
| Share Price | $1.15 |
|---|---|
| Market Cap | $54.4M |
| 52-Week Range | $0.73 – $2.52 |
| Shares Outstanding | 47.3 million (basic, 2026 Q2) |
RenovoRx Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $43,000 | $1.1M |
| Gross Profit | — | — | — | $43,000 | $796,000 |
| Operating Income | -$5.7M | -$9.9M | -$11.4M | -$11.0M | -$12.5M |
| Pre-Tax Income | -$6.3M | -$9.9M | -$10.2M | -$8.8M | -$11.2M |
| Income Tax | — | — | — | — | $2,000 |
| Net Income | -$6.3M | -$9.9M | -$10.2M | -$8.8M | -$11.2M |
| Diluted EPS | -$1.21 | — | -$0.99 | -$0.40 | -$0.32 |
RenovoRx Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $266,000 | $238,000 | $563,000 | $909,000 |
| Net Income | -$2.9M | -$2.9M | -$3.5M | -$2.9M |
| Diluted EPS | -$0.08 | -$0.08 | -$0.09 | -$0.06 |
RenovoRx Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $15.2M | $4.4M | $1.2M | $7.2M | $7.0M |
| Current Assets | $16.3M | $7.3M | — | $7.8M | $7.9M |
| Total Assets | $16.3M | $7.3M | $1.5M | $8.1M | $8.1M |
| Current Liabilities | $938,000 | — | $1.2M | $1.9M | $2.0M |
| Total Liabilities | $938,000 | $1.1M | $4.5M | $3.6M | $2.7M |
| Shareholders' Equity | $15.3M | $6.2M | -$3.0M | $4.5M | $5.4M |
RenovoRx Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$5.9M | -$8.8M | -$10.3M | -$9.1M | -$11.0M |
| Cash From Investing | -$15,000 | -$2.0M | $2.0M | -$12,000 | -$2,000 |
| Cash From Financing | $19.3M | $42,000 | $5.0M | $15.1M | $10.8M |
| Free Cash Flow | — | — | — | -$9.1M | -$11.0M |
Figures from RenovoRx's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full RenovoRx financials page for every line item.
RenovoRx Company Profile
| Ticker | RNXT |
|---|---|
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | Mountain View, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001574094 |
Frequently Asked Questions
What was RenovoRx's revenue in fiscal 2025?
RenovoRx (RNXT) reported revenue of $1.1M for fiscal 2025.
What is RenovoRx's annual revenue history?
RenovoRx's annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $43,000; 2025: $1.1M.
What was RenovoRx's net income in fiscal 2025?
RenovoRx reported net income of -$11.2M for fiscal 2025.
What was RenovoRx's earnings per share (EPS) in fiscal 2025?
RenovoRx's diluted EPS was -$0.32 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did RenovoRx generate in fiscal 2025?
RenovoRx generated -$11.0M of free cash flow in fiscal 2025.
What was RenovoRx's revenue last quarter?
In its most recent reported quarter (2026 Q2), RenovoRx reported revenue of $909,000.
How many shares of RenovoRx are outstanding?
RenovoRx reported a weighted average of 47.3 million basic shares outstanding in 2026 Q2.
What is RenovoRx's market cap?
Based on its latest closing price, RenovoRx (RNXT) has a market capitalization of about $54.4M.
When does RenovoRx's fiscal year end?
RenovoRx's fiscal year end, as registered with the SEC, is December 31.
Where is RenovoRx headquartered?
RenovoRx lists its business address in Mountain View, California in its SEC filings.